JP2005533780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533780A5 JP2005533780A5 JP2004512706A JP2004512706A JP2005533780A5 JP 2005533780 A5 JP2005533780 A5 JP 2005533780A5 JP 2004512706 A JP2004512706 A JP 2004512706A JP 2004512706 A JP2004512706 A JP 2004512706A JP 2005533780 A5 JP2005533780 A5 JP 2005533780A5
- Authority
- JP
- Japan
- Prior art keywords
- aids
- vomiting
- nausea
- formulation
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 25
- 241000218236 Cannabis Species 0.000 claims description 18
- 239000002552 dosage form Substances 0.000 claims description 17
- 208000030507 AIDS Diseases 0.000 claims description 15
- 206010047700 Vomiting Diseases 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 13
- 206010006895 Cachexia Diseases 0.000 claims description 10
- 238000002512 chemotherapy Methods 0.000 claims description 10
- 208000022531 anorexia Diseases 0.000 claims description 9
- 206010061428 decreased appetite Diseases 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 206010010904 Convulsion Diseases 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 5
- 208000014094 Dystonic disease Diseases 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 5
- 206010048010 Withdrawal syndrome Diseases 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 201000007930 alcohol dependence Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 229940049706 benzodiazepine Drugs 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000009429 distress Effects 0.000 claims description 5
- 208000010118 dystonia Diseases 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 201000005040 opiate dependence Diseases 0.000 claims description 5
- 230000001769 paralizing effect Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 230000000472 traumatic effect Effects 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 4
- 210000002200 mouth mucosa Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 206010028813 Nausea Diseases 0.000 claims description 3
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 3
- 229960004242 dronabinol Drugs 0.000 claims description 3
- 230000001037 epileptic effect Effects 0.000 claims description 3
- -1 flavours Chemical class 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 5
- 206010049119 Emotional distress Diseases 0.000 claims 4
- 230000002981 neuropathic effect Effects 0.000 claims 4
- 230000008673 vomiting Effects 0.000 claims 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 3
- 229950011318 cannabidiol Drugs 0.000 claims 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 3
- 235000019198 oils Nutrition 0.000 claims 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 2
- FXFYOPQLGGEACP-UHFFFAOYSA-N 6-methylcoumarin Chemical compound O1C(=O)C=CC2=CC(C)=CC=C21 FXFYOPQLGGEACP-UHFFFAOYSA-N 0.000 claims 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 150000001491 aromatic compounds Chemical class 0.000 claims 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229930003827 cannabinoid Natural products 0.000 claims 2
- 239000003557 cannabinoid Substances 0.000 claims 2
- 229960003453 cannabinol Drugs 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 229960005233 cineole Drugs 0.000 claims 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 claims 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 claims 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- 229920000936 Agarose Polymers 0.000 claims 1
- 239000001904 Arabinogalactan Substances 0.000 claims 1
- 229920000189 Arabinogalactan Polymers 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 claims 1
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims 1
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims 1
- 239000001293 FEMA 3089 Substances 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 244000043261 Hevea brasiliensis Species 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 235000019312 arabinogalactan Nutrition 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 claims 1
- 229930006739 camphene Natural products 0.000 claims 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 239000010628 chamomile oil Substances 0.000 claims 1
- 235000019480 chamomile oil Nutrition 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 claims 1
- 229930007050 cineol Natural products 0.000 claims 1
- 235000000484 citronellol Nutrition 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229940073505 ethyl vanillin Drugs 0.000 claims 1
- 239000010642 eucalyptus oil Substances 0.000 claims 1
- 229940044949 eucalyptus oil Drugs 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229940060367 inert ingredients Drugs 0.000 claims 1
- 235000001510 limonene Nutrition 0.000 claims 1
- 229940087305 limonene Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- 229960001047 methyl salicylate Drugs 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 229920003052 natural elastomer Polymers 0.000 claims 1
- 229920001194 natural rubber Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000010678 thyme oil Substances 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
- 239000010410 layer Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10226494A DE10226494A1 (de) | 2002-06-14 | 2002-06-14 | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| PCT/EP2003/004807 WO2003105800A2 (de) | 2002-06-14 | 2003-05-08 | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005533780A JP2005533780A (ja) | 2005-11-10 |
| JP2005533780A5 true JP2005533780A5 (enExample) | 2006-01-26 |
| JP4526384B2 JP4526384B2 (ja) | 2010-08-18 |
Family
ID=29719057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004512706A Expired - Fee Related JP4526384B2 (ja) | 2002-06-14 | 2003-05-08 | カンナビス活性成分の投与のためのフィルム型粘着性投与形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060039959A1 (enExample) |
| EP (1) | EP1513494A2 (enExample) |
| JP (1) | JP4526384B2 (enExample) |
| CN (1) | CN1658840A (enExample) |
| AU (1) | AU2003227735B2 (enExample) |
| BR (1) | BR0311867A (enExample) |
| CA (1) | CA2489106A1 (enExample) |
| DE (1) | DE10226494A1 (enExample) |
| IL (1) | IL165744A0 (enExample) |
| RU (1) | RU2324476C2 (enExample) |
| WO (1) | WO2003105800A2 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
| US9289583B2 (en) * | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US9066847B2 (en) * | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| GB2434312B (en) | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| DE102006027791A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | AchE-NMDA-Kombinationswafer |
| US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
| US8242178B2 (en) * | 2007-06-18 | 2012-08-14 | University Of South Carolina | Use of cannabidiol in the treatment of autoimmune hepatitis |
| GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| MX2011009859A (es) * | 2009-04-01 | 2011-09-29 | Colgate Palmolive Co | Compuestos derivados de mentol y uso de los mismos como agentes activos orales y sistemicos. |
| GB2471523A (en) * | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| US9781946B2 (en) * | 2010-05-27 | 2017-10-10 | Symrise Ag | Flavoring substance-included compounds |
| RU2453559C1 (ru) * | 2010-10-11 | 2012-06-20 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| US9399722B2 (en) | 2011-03-31 | 2016-07-26 | The Armor All/Stp Products Company | Compositions and methods for treating automotive surfaces |
| GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| WO2014159688A1 (en) | 2013-03-14 | 2014-10-02 | Sc Laboratories, Inc. | Bioactive concentrates and uses thereof |
| WO2015069763A2 (en) * | 2013-11-05 | 2015-05-14 | First Watersign Llc | Sublingual cannabis dosage form and methods of making and using the same |
| US11033493B2 (en) | 2013-12-02 | 2021-06-15 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
| US10272038B2 (en) * | 2013-12-02 | 2019-04-30 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
| US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
| US9380813B2 (en) | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
| US10821240B2 (en) | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
| US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| US9186386B2 (en) | 2014-04-17 | 2015-11-17 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| US10392178B2 (en) * | 2014-04-21 | 2019-08-27 | Zen Potion, Inc. | Preparing beverages containing cannabinoids using beverage containers with polymer matrices |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| EP3160451B1 (en) | 2014-06-27 | 2021-04-07 | Farm To Farma, Inc. | Buccal and sublingual cannabinoid formulations and method of making the same |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| WO2016092539A1 (en) * | 2014-12-07 | 2016-06-16 | One World Cannabis Ltd | Use of cannabis to treat migraine |
| WO2016106329A1 (en) | 2014-12-23 | 2016-06-30 | Acelrx Pharmaceuticals, Inc. | Systems, devices and methods for dispensing oral transmucosal dosage forms |
| US20160213027A1 (en) * | 2015-01-21 | 2016-07-28 | George Maniatakos | Pet food additive |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| KR20180019198A (ko) * | 2015-06-22 | 2018-02-23 | 존슨 앤드 존슨 컨수머 인코포레이티드 | 피부에 효과를 제공하기 위한 다층 국소-적용 물품 |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US20170112188A1 (en) * | 2015-10-22 | 2017-04-27 | John Ostrander | Wrapper For Enclosing Smokable Substances |
| US20170188616A1 (en) * | 2015-12-17 | 2017-07-06 | Therabis, Llc | Cannabinoid-enriched supplement |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| EP3538078A4 (en) * | 2016-11-11 | 2020-07-08 | Bennes, Inc. | FORMULATIONS FOR EFFICIENT CANNABINOID DELIVERY |
| JP2020500220A (ja) | 2016-11-15 | 2020-01-09 | クラリア ファーマ ホールディング エービー | 医薬製剤 |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| CN109394836A (zh) * | 2017-08-18 | 2019-03-01 | 汉义生物科技（北京）有限公司 | 一种预防和/或缓解痛经的大麻纤维及其在卫生用品中的应用 |
| CN109498606A (zh) * | 2017-09-15 | 2019-03-22 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
| US20190125660A1 (en) * | 2017-10-31 | 2019-05-02 | Calitas Therapeutics, Inc | Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| CN108743571B (zh) * | 2018-08-07 | 2020-10-02 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
| FR3084837B1 (fr) | 2018-08-10 | 2021-10-29 | Urgo Rech Innovation Et Developpement | Composition filmogene mucoadhesive et son utilisation pour le traitement des douleurs liees aux poussees dentaires |
| US10828254B2 (en) | 2018-09-28 | 2020-11-10 | Intelgenx Corp. | Oral film formulation for modulating absorption profile |
| US12303501B2 (en) | 2018-11-05 | 2025-05-20 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
| US11602504B2 (en) * | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
| DE102019100483A1 (de) | 2019-01-10 | 2020-07-16 | Lts Lohmann Therapie-Systeme Ag | Oraler Dünnfilm |
| CN110200953B (zh) * | 2019-06-15 | 2022-02-08 | 汉义生物科技（北京）有限公司 | 大麻素在制备吸入给药药物中的应用 |
| WO2021055079A1 (en) | 2019-09-16 | 2021-03-25 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
| US20210100737A1 (en) | 2019-10-03 | 2021-04-08 | Starton Therapeutics, Inc. | Transdermal delivery of dronabinol |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| WO2021070120A1 (en) | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| JP2022551730A (ja) | 2019-10-14 | 2022-12-13 | パイク セラピューティクス，インコーポレイテッド | カンナビジオールの経皮送達 |
| EP3808341A1 (de) * | 2019-10-16 | 2021-04-21 | ADD Advanced Drug Delivery Technologies, Ltd. | Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen |
| EP3808336A1 (de) * | 2019-10-16 | 2021-04-21 | ADD Advanced Drug Delivery Technologies, Ltd. | Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen |
| CN111150729B (zh) * | 2020-01-16 | 2021-02-12 | 全越 | 一种成膜组合物及其应用 |
| CN111228241B (zh) * | 2020-01-16 | 2023-08-04 | 全越 | 一种成膜组合物及其应用 |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| DE102020122557A1 (de) * | 2020-08-28 | 2022-03-03 | Lts Lohmann Therapie-Systeme Ag | Mucosa-Perforierung |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US20240325414A1 (en) * | 2021-07-22 | 2024-10-03 | Nicoventures Trading Limited | Constituent, derivative or extract of cannabis in a water soluble matrix |
| US11986008B2 (en) | 2021-09-01 | 2024-05-21 | David Addington | Method of processing cannabis |
| WO2025116961A1 (en) * | 2023-11-27 | 2025-06-05 | J.D.I.P., Llc | Cannabis compositions, oral products, and methods of making same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2046773B (en) * | 1979-03-21 | 1983-08-03 | Advance Tapes Uk Ltd | Gelatinous articles and compositions |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| WO1996000072A1 (en) * | 1994-06-23 | 1996-01-04 | The Procter & Gamble Company | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6328992B1 (en) * | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
| US5989535A (en) * | 1997-08-15 | 1999-11-23 | Soma Technologies | Polymeric bioadhesive emulsions and suspensions and methods of treatment |
| ATE314092T1 (de) * | 1997-09-26 | 2006-01-15 | Noven Pharma | Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen |
| US6509005B1 (en) * | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
| US6319510B1 (en) * | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
| US20030191180A1 (en) * | 2000-03-09 | 2003-10-09 | Calvin Ross | Pharmaceutical compositions |
| DE10051427C1 (de) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
| EP2298284A3 (en) * | 2001-02-14 | 2013-12-18 | GW Pharma Limited | Mucoadhesive pharmaceutical formulations |
| US6730330B2 (en) * | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
| US20030017216A1 (en) * | 2001-07-23 | 2003-01-23 | Schmidt Robert Gustav | Isolation of herbal and cannabinoid medicinal extracts |
| EP1539069A4 (en) * | 2002-05-31 | 2007-11-14 | Univ Mississippi | TRANSMUCOSAL DELIVERY OF CANNABINOIDS |
-
2002
- 2002-06-14 DE DE10226494A patent/DE10226494A1/de not_active Withdrawn
-
2003
- 2003-05-08 CA CA002489106A patent/CA2489106A1/en not_active Abandoned
- 2003-05-08 US US10/517,849 patent/US20060039959A1/en not_active Abandoned
- 2003-05-08 AU AU2003227735A patent/AU2003227735B2/en not_active Ceased
- 2003-05-08 WO PCT/EP2003/004807 patent/WO2003105800A2/de not_active Ceased
- 2003-05-08 JP JP2004512706A patent/JP4526384B2/ja not_active Expired - Fee Related
- 2003-05-08 CN CN038137291A patent/CN1658840A/zh active Pending
- 2003-05-08 BR BR0311867-3A patent/BR0311867A/pt not_active IP Right Cessation
- 2003-05-08 RU RU2005100953/15A patent/RU2324476C2/ru not_active IP Right Cessation
- 2003-05-08 EP EP03725174A patent/EP1513494A2/de not_active Withdrawn
-
2004
- 2004-12-13 IL IL16574404A patent/IL165744A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533780A5 (enExample) | ||
| JP4526384B2 (ja) | カンナビス活性成分の投与のためのフィルム型粘着性投与形態 | |
| CN1750809B (zh) | 含有药学活性剂的快速溶解的口腔可消耗薄膜 | |
| Hooda et al. | A review on oral mucosal drug delivery system | |
| JP2006503003A (ja) | 経口摂取できる剤形を作製する方法 | |
| JP5841151B2 (ja) | 鼻腔噴霧剤 | |
| JP2006524675A (ja) | 甘味料としてのスクラロースを含有する経口消耗急速溶解性フィルム | |
| JP2003510279A (ja) | 改善された安定性を有する組成物 | |
| JP2001508038A (ja) | 粘膜表面および身体組織に付与可能な薬学的ゲル調製物 | |
| JP2008540649A5 (enExample) | ||
| KR20090020561A (ko) | 필름 피복된 고체 투여 형태 | |
| CN1812765B (zh) | 具有降低的粘膜刺激的经粘膜给药剂型 | |
| JP2014500258A5 (enExample) | ||
| US20040131661A1 (en) | Process for making orally consumable dosage forms | |
| Sheoran | Buccal drug delivery system: A review | |
| HUP0105028A2 (hu) | Javított stabilitású készítmények és eljárás az előállításukra | |
| WO2021112812A2 (en) | Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids | |
| US12383591B2 (en) | Chewing gum containing synergistic medicinal compounds | |
| AU2004273574B2 (en) | Buccal formulations of galanthamine and uses thereof | |
| JP2006316009A (ja) | 口腔内貼付剤及びその製造方法 | |
| JP2007512270A (ja) | デオキシペガニンの経口製剤およびそれらの使用 | |
| KR20050021003A (ko) | 대마 활성 성분의 투여용 필름 형상의 점막접착성 투여 제형 | |
| JP2007099689A (ja) | 眠気防止用口蓋貼付用フィルム。 | |
| Sharma et al. | Different Variable and Recent Development in Noval Buccal Drug Delivery System | |
| JP2007099688A (ja) | 鼻炎症状改善用口蓋貼付用フィルム。 |